Send to

Choose Destination
Clin Exp Vaccine Res. 2012 Jul;1(1):70-6. doi: 10.7774/cevr.2012.1.1.70. Epub 2012 Jul 31.

Development of a novel vaccine against canine parvovirus infection with a clinical isolate of the type 2b strain.

Author information

Department of Veterinary Infectious Diseases, College of Veterinary Medicine, Konkuk University, Seoul, Korea.



In spite of an extensive vaccination program, parvoviral infections still pose a major threat to the health of dogs.


We isolated a novel canine parvovirus (CPV) strain from a dog with enteritis. Nucleotide and amino acid sequence analysis of the isolate showed that it is a novel type 2b CPV with asparagine at the 426th position and valine at the 555th position in VP2. To develop a vaccine against CPV infection, we passaged the isolate 4 times in A72 cells.


The attenuated isolate conferred complete protection against lethal homologous CPV infection in dogs such that they did not develop any clinical symptoms, and their antibody titers against CPV were significantly high at 7-11 days post infection.


These results suggest that the virus isolate obtained after passaging can be developed as a novel vaccine against paroviral infection.


Canine parvoviral infection; Clinical isolate; Dogs; Novel type 2b; Vaccines

Supplemental Content

Full text links

Icon for The Korean Vaccine Society Icon for PubMed Central
Loading ...
Support Center